178 related articles for article (PubMed ID: 34125982)
1. Giant cell tumor of bone - Analysis of 213 cases involving extra-craniofacial bones.
Konishi E; Outani H; Mano M; Nagata S; Shirai T; Naka N; Hori Y; Takenaka S; Haga H; Toguchida J; Kakunaga S; Kuwae Y; Hoshi M; Inoue T; Aono M; Morinaga Y; Nakashima Y
Pathol Int; 2021 Aug; 71(8):500-511. PubMed ID: 34125982
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture.
Medellin MR; Fujiwara T; Tillman RM; Jeys LM; Gregory J; Stevenson JD; Parry M; Abudu A
Bone Joint J; 2018 Dec; 100-B(12):1626-1632. PubMed ID: 30499317
[TBL] [Abstract][Full Text] [Related]
4. Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone.
Li D; Zhang J; Li Y; Xia J; Yang Y; Ren M; Liao Y; Yu S; Li X; Shen Y; Zhang Y; Yang Z
World J Surg Oncol; 2016 Apr; 14():114. PubMed ID: 27094617
[TBL] [Abstract][Full Text] [Related]
5. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
[TBL] [Abstract][Full Text] [Related]
6. Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones.
van der Heijden L; van de Sande MA; Dijkstra PD
Acta Orthop; 2012 Aug; 83(4):401-5. PubMed ID: 22880716
[TBL] [Abstract][Full Text] [Related]
7. Chondroblastoma of extra-craniofacial bones: Clinicopathological analyses of 103 cases.
Konishi E; Nakashima Y; Mano M; Tomita Y; Kubo T; Araki N; Morii E; Yoshikawa H; Haga H; Toguchida J; Ueda T; Osawa M; Hoshi M; Inoue T; Aono M; Yanagisawa A
Pathol Int; 2017 Oct; 67(10):495-502. PubMed ID: 28971570
[TBL] [Abstract][Full Text] [Related]
8. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
Ud Din N; Umer M; Park YK
Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
[No Abstract] [Full Text] [Related]
9. Factors of local recurrence of giant cell tumor of long bone after treatment: plain radiographs, pathology and surgical procedures.
Chanchairujira K; Jiranantanakorn T; Phimolsarnti R; Asavamongkolkul A; Waikakul S
J Med Assoc Thai; 2011 Oct; 94(10):1230-7. PubMed ID: 22145509
[TBL] [Abstract][Full Text] [Related]
10. Similar local recurrence but better function with curettage versus resection for bone giant cell tumor and pathological fracture at presentation.
Tsukamoto S; Mavrogenis AF; Tanzi P; Leone G; Righi A; Akahane M; Kido A; Honoki K; Tanaka Y; Donati DM; Errani C
J Surg Oncol; 2019 Jun; 119(7):864-872. PubMed ID: 30734307
[TBL] [Abstract][Full Text] [Related]
11. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
[TBL] [Abstract][Full Text] [Related]
12. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
[TBL] [Abstract][Full Text] [Related]
13. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
[TBL] [Abstract][Full Text] [Related]
14. Local recurrence after curettage treatment of giant cell tumors in peripheral bones: retrospective study by the GSF-GETO (French Sarcoma and Bone Tumor Study Groups).
Gouin F; Dumaine V;
Orthop Traumatol Surg Res; 2013 Oct; 99(6 Suppl):S313-8. PubMed ID: 23978709
[TBL] [Abstract][Full Text] [Related]
15. In-depth analysis of local recurrence of giant cell tumour of bone with soft tissue extension after intralesional curettage.
Chen L; Ding XY; Wang CS; Si MJ; Du LJ; Zhang WB; Lu Y
Radiol Med; 2014 Nov; 119(11):861-70. PubMed ID: 24604549
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological Features of a Series of 27 Cases of Post-Denosumab Treated Giant Cell Tumors of Bones: A Single Institutional Experience at a Tertiary Cancer Referral Centre, India.
Rekhi B; Verma V; Gulia A; Jambhekar NA; Desai S; Juvekar SL; Bajpai J; Puri A
Pathol Oncol Res; 2017 Jan; 23(1):157-164. PubMed ID: 27722984
[TBL] [Abstract][Full Text] [Related]
17. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
Agarwal MG; Gundavda MK; Gupta R; Reddy R
Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215
[TBL] [Abstract][Full Text] [Related]
18. Convolutional neural network to predict the local recurrence of giant cell tumor of bone after curettage based on pre-surgery magnetic resonance images.
He Y; Guo J; Ding X; van Ooijen PMA; Zhang Y; Chen A; Oudkerk M; Xie X
Eur Radiol; 2019 Oct; 29(10):5441-5451. PubMed ID: 30859281
[TBL] [Abstract][Full Text] [Related]
19. Denosumab for Bone Giant Cell Tumor of the Distal Radius.
Tsukamoto S; Mavrogenis AF; Tanzi P; Leone G; Ciani G; Righi A; Akahane M; Honoki K; Tanaka Y; Donati DM; Errani C
Orthopedics; 2020 Sep; 43(5):284-291. PubMed ID: 32745221
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance feature of "paintbrush borders" sign as a novel way to predict recurrence of giant cell tumor of bone after curettage: a pilot study.
He Y; Wang J; Zhang J; Du L; Lu Y; Xu J; Yuan F; Tan Y; Ding X
J Int Med Res; 2018 Feb; 46(2):710-722. PubMed ID: 29239274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
